Close Menu

by Jim Reddoch

The stock market has had a rough year, but the performance of the Nasdaq — down 15 percent — is downright enviable for biotech investors. The BTK stock average is down 28 percent for 2002 to date. Genomics stocks have largely tracked the BTK in ’02, but underperformed in 2001.

This column takes on the idea of “trough valuations,” or in other words, how low can they go?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.